Intra-arterial thrombolysis via urokinase following reperfusion by endovascular thrombectomy for stroke does not affect survival without disability.

A new meta-analysis examines the effects of dual antiplatelet therapy after thrombolysis in minor stroke patients. Findings ...

Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

Intra-arterial thrombolysis with urokinase or tenecteplase after successful endovascular thrombectomy (EVT) did not significantly improve outcomes in patients with acute ischemic stroke ...

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effecti ...

Hospitals serving disadvantaged communities are less likely to administer IV thrombolysis for stroke, compared with hospitals in more affluent areas, a new study suggests.

Tenecteplase thus officially joins the other stroke thrombolytic approved stateside, alteplase (Activase), which is also marketed by Genentech. Notably, off-label tenecteplase had already become ...

NHS pressures and “deep inequalities in care” are “failing” stroke patients, according to a report. The Stroke Association also warned that some patients face a “postcode lottery” for life-saving ...

Acute ischemic stroke, which occurs due to a blockage in cerebral blood flow, requires prompt intervention with thrombolytic ...

Clinuvel Pharmaceuticals (ASX:CUV) has reported encouraging preliminary results from its second study of afamelanotide in ...

HealthDay News — For patients with ischemic stroke, tenecteplase seems to be ... included for 79,550 patients treated with intravenous thrombolysis, of whom 11.9% and 88.1% received tenecteplase ...